Urinary tract infection drug recalled. Tablets could be tainted and deadly
The spotting of spots 'was reported in a product quality complaint,' Amneal Pharmaceuticals said in its FDA-posted recall notice about Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80 mg.
As for what problems this might cause, Amneal's notice said: 'Oral products contaminated with Aspergillus may result in serious and life-threatening infections. The use of the defective product in patients with underlying immunosuppressive conditions increases the concern for serious infections.'
Sulfamethoxazole/Trimethoprim is used for UTIs caused by a broad list of strains, among which are E. coli; middle-ear infections in children; streptococcus pneumoniae aka pneumococcus, which the Cleveland Clinic says can cause pneumonia, sepsis or bacterial meningitis; and 'traveler's diarrhea.'
READ MORE: USDA public health alert: E. coli found in beef sent to Whole Foods stores
What exactly has been recalled?
Recalled tablets with 400 mg of Sulfamethoxazole and 80 mg Trimethoprim went to wholesalers and distributors around the nation from Dec. 4 through May 15. If you have these tablets but got them before Dec. 4, you're safe.
Bottles in lot No.s AM241019 and AM241020 are 100-count bottles. Bottles in lot No. AM241019A have 500 tablets.
If you're taking these drugs, for instructions on returning them or to ask questions about this recall, contact Amneal at 833-582-0812, Monday through Friday, 8 am. to 5 p.m., Eastern time; email sulfamethoxazole-trimethoprim-recall@amneal.com; or fax to 631-983-2595.
If you experience any medical problems, tell a medical provider. Then inform the FDA's MedWatch program, either online or by downloading a form, then faxing it to 800-332-0178. If you can't download a form, call 800-332-1088 to ask for a form.
Then you should report the problem to Amneal at 877-835-5472, Monday through Friday, 8 a.m. to 6 p.m., Eastern time or by emailing DrugSafety@amneal.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
an hour ago
- CNN
5 things to know for July 25: Thailand-Cambodia, France, AI, Sanctuary city lawsuit, Skydance-Paramount merger
In addition to telling time, smartwatches can track your steps, heart rate, blood pressure and sleeping patterns. Now, a smartwatch has helped search and rescue teams locate a small plane after it crashed into the dense forests near West Yellowstone, Montana. Here's what else you need to know to get up to speed and on with your day. More than 100,000 civilians have been displaced following a second day of violence along the disputed 500-mile land border between Thailand and Cambodia. At least 16 people were also reportedly killed, officials from both countries said. Tensions between the Southeast Asian neighbors have been boiling for months. Around 4:30 a.m. local time on Friday, clashes broke out with Cambodian troops using small arms and heavy weapons and Thai troops responding with artillery fire. On Thursday, when Thailand deployed fighter jets to attack Cambodian military targets, Cambodia vowed to 'respond decisively.' French President Emmanuel Macron said on Thursday that France will recognize a Palestinian state in an announcement at the UN General Assembly in September. France will be the first member of the UN Security Council and the G7 nations to do so. 'We must build the state of Palestine, ensure its viability, and ensure that by accepting its demilitarization and fully recognizing Israel, it contributes to the security of all in the Middle East. There is no alternative,' he wrote on X. Macron also called for an immediate ceasefire, access to humanitarian aid for the population of Gaza, the release of all hostages and the demilitarization of Hamas. Secretary of State Marco Rubio said the US 'strongly rejects' Macron's plan. The Department of Health and Human Services (HHS) has started using artificial intelligence, and behind the scenes, the practice has caused some alarm. An AI project known as Elsa is supposed to help speed up drug and medical device approvals at the FDA, a division of HHS. Six current and former FDA officials told CNN that Elsa can be useful for generating meeting notes and summaries, or email and communique templates, but it also invented studies and misrepresented research. In at least one instance — when an employee asked Elsa to generate something for a project — it insisted that the research area was not in the FDA's purview, even though it was. Elsa also cannot help with the lengthy assessment process that agency scientists undertake to determine whether drugs and devices are safe and effective because it can't access many of the files needed to answer basic questions. The Justice Department has filed a lawsuit against New York City over its so-called 'sanctuary city' policies. The move comes just days after the Trump administration blamed those policies for the shooting of an off-duty US Customs and Border Protection officer in an apparent robbery gone wrong. As part of the administration's widespread crackdown on undocumented immigrants, similar lawsuits have also been filed against Colorado, Illinois, Los Angeles, New York state, the city of Rochester, New York, and several New Jersey cities, the DOJ said in a statement. NYC Mayor Eric Adams said the city will review the lawsuit. 'Keeping New Yorkers safe also means making sure they feel safe, and we have been clear: no one should be afraid to dial 911, send their kids to school or go to the hospital, and no New Yorker should feel forced to hide in the shadows,' Adams said in a statement. The FCC approved the pending merger between Skydance Media and Paramount Global on Thursday. Voting 2-1 along party lines, the commissioners gave the go-ahead to the $8 billion deal, which has been mired in allegations of political interference stemming from President Trump's scathing criticism and his lawsuit against Paramount's CBS News division. But on July 1, Paramount agreed to pay $16 million toward Trump's future presidential library to resolve his legally dubious suit about an edit made to a '60 Minutes' interview with then-Vice President Kamala Harris before the November presidential election. Although Paramount and the FCC both insisted that the payout was unrelated to the merger review process, many likened it to a 'bribe.' GET '5 THINGS' IN YOUR INBOX If your day doesn't start until you're up to speed on the latest headlines, then let us introduce you to your new favorite morning fix. Sign up here for the '5 Things' newsletter. Amy Sherald, who gained national fame for her official portrait of former first lady Michelle Obama in 2018, was told that the museum had 'concerns' about one of her paintings. The head of human resources at the New York-based tech company and her boss were seen embracing on the 'kiss cam' during a Coldplay concert. Video of the encounter quickly went viral. The 12-year-old baseball player faced suspension for what he did last week after hitting a game-winning home run. High cocoa costs are prompting a major confectionery company to hike prices for chocolate candy. 'What have you done?' Victoria Beckham, the soccer star's wife, asked when she saw it. Legendary jazz musician Chuck Mangione diesThe noted flugelhorn player, trumpeter and composer became known for his signature tune 'Feels So Good,' which spent 25 weeks on the Billboard Hot 100 chart, peaking at #4 in 1978. Throughout his six-decade career in music, Mangione received 14 Grammy nominations and won the award twice. He also made recurring appearances on the Fox animated series 'King of the Hill,' where he played a tongue-in-cheek version of himself. Which city may soon become the first modern capital in the world to run completely out of water?A. Kabul, AfghanistanB. Mexico City, MexicoC. Baghdad, IraqD. Sanaa, Yemen Take me to the quiz! $250That's how much the US plans to charge international visitors for a new 'visa integrity fee.' The provision was included in President Trump's recently enacted domestic policy bill. 'Crazy!! My House got Home Invaded Saturday While I was in Indianapolis performing for the WNBA all star game & instead of Focusing on finding the Suspects, they focus on some cannabis.' — GloRilla on X. The Grammy-nominated rapper is facing felony drug charges after police responded to her Georgia home following a separate report of a burglary in progress. 🌤️ Check your local forecast to see what you can expect. This Swiss river is so clean that locals use it to commute to their jobs. Today's edition of 5 Things AM was edited and produced by CNN's Andrew Torgan.
Business Wire
an hour ago
- Business Wire
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of ~$43 million. ANKTIVA ® Unit Growth Since J-Code: 246% unit sales volume growth in 1H 2025 compared to 2H 2024. Cash Position: $153.7 million in cash, cash equivalents and marketable securities as of June 30, 2025. NSCLC: Initiated randomized clinical trial (RCT) ResQ201A with N-803 + tislelizumab in 2 nd line lung cancer; US sites initiated, submitted clinical trial applications in EU, UK; Canada and Asia filings planned. Lymphopenia: FDA supportive of new data; reaffirmed RMAT/EAP; collaborative discussion outlining regulatory endpoints, trial design and registrational pathways to full approval for the treatment of lymphopenia with randomized trial design in progress. Full Enrollment Reached in the Randomized NCI Cancer Prevention Clinical Trial Using ANKTIVA + Adenovirus Vaccine in 186 Patients with Lynch Syndrome. United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) marketing authorization application of ANKTIVA approved. Papillary NMIBC: Discussion with FDA regarding filing status of supplemental BLA. ImmunityBio performing ongoing evaluation of next steps to address the Refuse to File decision by the FDA, following June Type A meeting with the Agency. New updated data on Papillary disease provided to the FDA and discussions with Agency to continue. Separately, ImmunityBio has applied to the National Comprehensive Cancer Network (NCCN) to seek expansion of the BCG-unresponsive NMIBC guidelines to include papillary-only disease. Financial Overview In the second quarter of 2025, ImmunityBio reported $26.4 million in revenue, representing a 60% increase from $16.5 million in the first quarter of 2025. This growth reflects continued commercial traction of ANKTIVA + BCG in BCG-unresponsive non-muscle invasive bladder cancer with CIS with or without Papillary tumors. The 1H 2025 sales of $42.9 million represents a 246% increase in unit volume during the first two quarters of 2025 since the J-code approval versus the last two quarters of 2024. The Company ended the quarter with $153.7 million in cash, cash equivalents and marketable securities as of June 30, 2025. Non-Muscle Invasive Bladder Cancer (Papillary NMIBC) ImmunityBio conducted a Type A meeting with the FDA in June to discuss its program targeting papillary-only NMIBC and the Agency's response to the supplemental BLA filing. Contrary to the advice the FDA gave the Company in January 2025 to submit the supplemental BLA, the FDA responded with a Refuse-to-File (RTF) notice in May on the basis of requiring a randomized controlled trial (RCT) against chemotherapy. At the June meeting, ImmunityBio provided new data regarding the updated results since the initial BLA filing of papillary only data as well as real-world data of chemotherapy just published in this indication. In the papillary only NMIBC new data based on 26 of the 100 subjects in Cohort A and 80 subjects in Cohort B (Papillary Alone) of our QUILT-3.032 trial, demonstrated long-term (36-month) progression free survival and bladder sparing with ANKTIVA + BCG. ImmunityBio presented the newly published real-world data which demonstrates that compared to chemotherapy, ANKTIVA + BCG led to improved outcomes of progression free survival and cystectomy avoidance at 36-months. To our knowledge, the results to date of ANKTIVA + BCG represent the longest duration of follow-up with the longest duration of bladder sparing in these subjects. The Company indicated at the meeting that it would seek a new meeting request with this new data and withdraw the prior supplemental BLA filing; however, the Company is re-evaluating this approach in consultation with its regulatory counsel and may seek to amend the initial filing with the new data rather than withdrawing it, with a commitment to initiate a randomized controlled trial of chemotherapy free ANKTIVA + BCG versus chemotherapy in the papillary alone indication. Separately, ImmunityBio has applied to the National Comprehensive Cancer Network (NCCN) to seek expansion of the BCG-unresponsive NMIBC guidelines to include papillary-only disease, in addition to the currently recognized CIS with or without papillary disease. The NCCN is expected to review the submission at its August 2025 meeting. Non-Small Cell Lung Cancer (NSCLC) ImmunityBio has launched ResQ201A, a randomized controlled trial, in the United States, evaluating its IL-15 superagonist N-803 in combination with tislelizumab, a PD-1 checkpoint inhibitor from BeOne Medicines in patients with 2 nd line lung cancer who were progressing on checkpoint inhibitors. The Company has also submitted clinical trial applications for ResQ201A in the European Union and the United Kingdom, with Canada expected to be submitted in early Q3 2025, and with plans underway to submit in Asia. Lymphopenia The Company also met with the Division of Non-Malignant Hematology at the FDA in June to present updated data from its lymphopenia program. The Division was supportive of the findings including the underlying science of stimulating lymphocytes with ANKTIVA and expressed a desire to support an efficient path to approval, noting that additional time will be required to finalize the appropriate development plan. Expanded Access Program (EAP) authorization has been activated for the indication for all solid tumors in patients who have failed first-line treatment on chemotherapy, radiotherapy or immunotherapy and exhibit low Absolute Lymphocyte Counts (ALC < 1,000/μL). Disclaimer Regarding Financial Overview The information and amounts presented above, including under the caption 'Financial Overview,' reflects the Company's preliminary estimates based solely upon information available to it as of the date of this press release, and the amounts reported are not a comprehensive statement of its financial results or position as of June 30, 2025. Any actual amount that the Company reports in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 will be subject to its financial closing procedures and any final adjustments that may be made prior to the time its financial results for the period ended June 30, 2025 are finalized. As a result, these preliminary estimates may differ materially from the actual results that will be reflected in the Company's condensed consolidated financial statements for the quarter when they are completed and publicly disclosed. About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 and by UK MHRA in 2025 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding discussions and meetings with the U.S. FDA, including with respect to the previously reported RTF letter received by the Company and potential implications thereof, potential next steps, decisions and timeline related to the Company's regulatory submissions and strategy, financial results anticipated to be reported in future SEC filings, clinical trial data and potential results and implications to be drawn therefrom, the expectation that the EAP described herein will enable patients to have access to ANKTIVA for the indication described, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, clinical trial and expanded access program enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield TM platform, anticipated review timeline for the Company's NCCN guidelines submission in NMIBC papillary only and potential implications therefrom, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iii) risks and uncertainties regarding commercial launch execution, success and timing, (iv) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (v) whether clinical trials will result in registrational pathways and the risks, (vi) whether clinical trial data will be accepted by regulatory agencies, (vii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (viii) potential delays in product availability and regulatory approvals, (ix) ImmunityBio's ability to retain and hire key personnel, (x) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xi) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, (xiv) whether the NCCN will review and/or approve the Company's submission described herein on the anticipated timeline or at all, and (xv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
Yahoo
2 hours ago
- Yahoo
GSK's Blenrep combos approved for multiple myeloma in EU
GSK has secured approval in the European Union (EU) for Blenrep combinations to treat adults with relapsed or refractory multiple myeloma. The therapy received approval for use in combination with bortezomib plus dexamethasone (BVd) and pomalidomide plus dexamethasone (BPd) in patients who had received a minimum of one previous therapy, including lenalidomide. The approval was supported by efficacy results from the pivotal DREAMM-7 and DREAMM-8 Phase III trials, which demonstrated clinically meaningful improvements in progression-free survival (PFS) for Blenrep combinations compared to standard triplet therapies in both studies. In DREAMM-7, Blenrep combinations also showed improved overall survival (OS) compared to a daratumumab-based triplet. The tolerability and profiles of the combinations were consistent with the established profiles of the individual components. GSK oncology research and development global head and senior vice-president Hesham Abdullah stated: 'Today's approval of Blenrep combinations is a redefining moment for patients with relapsed or refractory multiple myeloma in the EU. 'Blenrep has the potential to extend remission and survival, with superior efficacy versus standards of care in our DREAMM clinical trial programme and the option to administer in both academic and community-based settings.' The combinations also secured approval in relapsed or refractory multiple myeloma in Japan, the UK and other markets, including Switzerland and Canada, based on the findings from DREAMM-8. Meanwhile, the US Food and Drug Administration (FDA) has extended the review period for the biologics licence application (BLA) submitted by the company for Blenrep combinations for the same indication. The new Prescription Drug User Fee Act action date is set for 23 October 2025, allowing the FDA additional time to evaluate the supplementary information provided in support of the BLA. "GSK's Blenrep combos approved for multiple myeloma in EU" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
